| 4.51 0.39 (9.47%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.64 |
1-year : | 6.58 |
| Resists | First : | 4.82 |
Second : | 5.64 |
| Pivot price | 4.1 |
|||
| Supports | First : | 4.16 |
Second : | 3.75 |
| MAs | MA(5) : | 4.13 |
MA(20) : | 4.15 |
| MA(100) : | 3.99 | MA(250) : | 6.04  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 61.5 |
D(3) : | 45.2 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 13.1 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALMS ] has closed It is unclear right now based on current values. 51.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 79 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.54 - 4.55 | 4.55 - 4.57 |
| Low: | 4.04 - 4.06 | 4.06 - 4.08 |
| Close: | 4.48 - 4.51 | 4.51 - 4.54 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Wed, 21 May 2025
Alumis-ACELYRIN Merger Creates Powerhouse in Immune Disease Drug Development with 2027 Cash Runway - Stock Titan
Wed, 21 May 2025
Alumis Completes Merger with ACELYRIN - TradingView
Tue, 13 May 2025
Alumis-ACELYRIN Merger Gets Green Light: Major Breakthrough for Immune Disease Treatment Pipeline - Stock Titan
Tue, 06 May 2025
Alumis director Srinivas Akkaraju buys shares worth $1.48 million - Investing.com
Tue, 22 Apr 2025
Alumis stock price target cut to $14 by H.C. Wainwright - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 7.105e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 1,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.1604e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 532.5 % |
| Return on Equity (ttm) | -59.9 % |
| Qtrly Rev. Growth | 2.005e+007 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -3.67 |
| Qtrly Earnings Growth | 33.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -345 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 24.89 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.37e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|